Expression of Th17 cell population regulatory cytokines in laryngeal carcinoma – Preliminary study

Abstract

Aim of the studyAim of the study was to evaluate the potential role of regulatory and proinflammatory cytokines IL-23 and IL-17 as Th17 lymphocyte activity markers in relation to invasiveness in laryngeal cancer.Material and methodsThe immunological analysis was conducted in 50 patients treated for squamous cell laryngeal carcinoma and 30 healthy volunteers as controls. The levels of IL-23 and IL-17 in supernatants of purified peripheral blood mononuclear cell cultures were determined by using the enzyme-linked immunosorbent assay (ELISA). The clinicomorphological criteria included pTNM, stage, G, and the total tumour front grading (TFG) score.ResultsOur data demonstrated higher concentrations of IL-23 in patients as compared to controls (p = 0.0001). No statistical difference for IL-17 in these groups was observed. Our study revealed significant dependences in IL-23 expression on pT (p = 0.04), histological differentiation (p = 0.04), and TFG total score (p = 0.02). Advanced tumours (pT3–pT4) with higher grade (G2–G3) and higher invasiveness (> 14 TFG points) were characterised by elevated IL-23 levels in PBMC supernatants. Our data did not indicate a relationship between cytokine levels and three- and five-year survival. However, a tendency towards lower content of IL-23 in PBMC cultures in patients who lived longer than five years after treatment was noted. The relationships between IL-17 level in PBMC cultures and clinicomorphological and prognostic parameters have not been disclosed.ConclusionsThe results of this study suggest the importance of regulatory cytokine IL-23 in determining the aggressive potential of laryngeal carcinomas.

Serum cytokine profile of laryngeal squamous cell carcinoma patients

“…In the present study, serum IL-17 levels did not correlate significantly with the presence of laryngeal SCC, tumour size or nodal involvement. Similar results were reported in a recent study in laryngeal SCC patients, although slightly higher IL-17 concentrations were noted in the control group 36 …”

Serum IL-8 acts as a novel biomarker in the diagnosis of patients with laryngeal cancer

“…in laryngeal cancer might inhibit aggressive tumor development, thus contributing to a relatively good prognosis [24]. Kopta R et al found that cytokines IL-23 played critical roles in determining the aggressive potential of laryngeal cancer [25]. The levels of cytokines may be sensitivity and reliable in re ecting tumor microenvironment which hold the capacity to serve as tumor biomarkers.…”

IL-17 Affects the Progression, Metastasis, and Recurrence of Laryngeal Cancer via the Inhibition of Apoptosis through Activation of the PI3K/AKT/FAS/FASL Pathways

“…The IL-17F has the highest degree of homology to IL-17A in the family. T helper cell 17-secreting cells (Th17) are the primary source of IL-17, while other cell types also develop this cytokine, such as group 3 innate lymphoid cells (ILC3), δγ T cells, and natural killer (NK) cells [ 4 – 6 ]. Some evidence has suggested that IL-17 is a key proinflammatory cytokine for the induction of cytokine and chemokine secretions by other cell types, among which mesenchymal cells and myeloid cells can recruit monocytes and neutrophils for inflammation [ 7 , 8 ].…”

“…Given the roles of IL-17 in transducing multiple signals in cells, IL-17 also activates Src to promote cancer development [ 6 ]. For example, the PI3K/AKT signaling pathway is one of the major Src-activating pathways and may block the FAS-associated death domain protein to inhibit cellular apoptosis [ 24 , 25 ].…”